SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Silberstein David S. (Last) (First) (Middle) 124 BYTE DRIVE (Street) FREDERICK, MD 21702 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 06/10/2020	3. Issuer Name and Ticker or Trading Symbol Lantern Pharma Inc. [ LTRN ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,044,000(1)(2)	I	See Explanation of Responses.(2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	(3)	(3)	Common Stock	5,096(1)(3)	$1.03(1)	D

Explanation of Responses:

1. In connection with the Issuer's initial public offering ("IPO"), the Issuer intends to effect a 1.74-for-1 stock split on its outstanding common stock, which will become effective immediately before the closing of the Issuer's IPO ("Stock Split"). The share amounts and the price reflect the anticipated Stock Split.

2. The securities beneficially owned by the Reporting Person consists of 1,044,000 shares of common stock held of record by Biological Mimetics, Inc. ("BMI"). Dr. Silberstein is a director of BMI and shares voting and investment control with respect to shares held by BMI. Because of the relationship between Dr. Silberstein and BMI, Dr. Silberstein may be deemed to beneficially own the shares held directly by BMI. Dr. Silberstein disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

3. The securities beneficially owned by the Reporting Person consists of 5,096 shares of common stock subject to options exercisable within 60 days.

	/s/ David S. Silberstein	06/10/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.